Cat. No.: HY-L184

Anti-Gastric Cancer Compound Library

83 Cited Publications

Customer Review

Based on 83 publication(s) in Google Scholar

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 1,181 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

PDF
Excel
SDF
Manual

Size

Price

Stock

Quantity

In-stock

(2-3 weeks)

Get a Quotation Now

In-stock

(2-3 weeks)

Get a Quotation Now

(2-3 weeks)

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Description & Advantages
Product Details
- Formulation
- Layout
- Container
- Storage
- Shipping
Publications (83)
Documentation
Composition

Description & Advantages

• A unique collection of 1,181 compounds with definite or potential anti-gastric cancer activity for high throughput screening (HTS) and high content screening (HCS).

• The compound library targets include PD-1, CTLA-4, p38 MAPK etc.

• A useful tool for the discovery of compounds for stomach neoplasm.

• Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.

• Structurally diverse, bioactive, and cell permeable.

• More detailed compound information with structure, IC50, and other chemical & biological data.

• High purity and quality validated by NMR and LC/MS.

• All compounds are in stock and continuously updated.

Product Details

Formulation

A collection of 1,181 anti-gastric cancer compounds supplied as pre-dissolved Solutions or Solid.

Solution: 1,139 compounds supplied in 10 mM solution, 41 compounds supplied in 2 mM solution, 1 compounds supplied in 3 mg/mL solution.

Layout

96-well storage tube or 96-well plate: 1st and 12th column are left empty.
384-well plate: the first two columns and the last two columns are left empty.
Compounds with different concentrations or dissolved in different solvents will be put on separate plates.
This way of layout may increase the number of plates because there could be three solvents and three concentrations.
If you have other requirements, please let us know.

Container

96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

Storage

-80°C

Shipping

Blue ice or dry ice